Fig. 2. Association between the Blue_response signature score and the rate of pathological complete response (pCR) in TMO-based breast cancer cohorts treated with neoadjuvant chemotherapy.

      We developed an algorithm to calculate absolute Blue_response signature scores independently of cohort-wide data. This enables direct comparison of scores across TMO arrays (a total of 33 cohorts in this study) and allows for the calculation of signature scores for newly added individual samples.  All samples were stratified into three groups based on their signature scores: low (≤30), medium (30–60), and high (>60). The pCR rates were then compared among these groups.  Data for the 46 non-TMO breast cancer cohorts is presented in Fig.3.